SCHEMBL1879159

SCHEMBL1879159

Cc1cccc(-c2cc(-c3ccccc3C#N)c(=O)n(-c3ccccc3)c2)n1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.71
GRIA3 P42263 1/20 0.71
PDE4D Q08499 1/20 0.71
TGFBR1 P36897 2/20 0.41
GAA P10253 2/20 0.41
GABRA1 P14867 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA2 P47869 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
GRM5 P41594 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890209 0.88 GRIA1 (0.72) GRIA1GRIA3PDE4DGAAGABRA1
SCHEMBL1884817 0.87 GRIA1 (0.71) GRIA1GRIA3PDE4DGABRA1GABRG2
SCHEMBL1881948 0.87 GRIA1 (0.71) GRIA1GRIA3PDE4DGABRA1GABRG2
SCHEMBL1885325 0.86 GRIA1 (0.67) GRIA1GRIA3PDE4DTGFBR1MEN1
SCHEMBL1887594 0.83 GRIA1 (0.66) GRIA1GRIA3PDE4DMEN1LMNA
Perampanel SCHEMBL31069847 0.83 GRIA1 (1.00) GRIA1GRIA3PDE4DGABRA1GABRG2
Perampanel SCHEMBL4214584 0.83 GRIA1 (1.00) GRIA1GRIA3PDE4DGABRA1GABRG2
Perampanel SCHEMBL194370 0.83 GRIA1 (1.00) GRIA1GRIA3PDE4DGABRA1GABRG2
Perampanel SCHEMBL29354621 0.83 GRIA1 (1.00) GRIA1GRIA3PDE4DGABRA1GABRG2
Perampanel SCHEMBL2857277 0.83 GRIA1 (1.00) GRIA1GRIA3PDE4DGABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8525129-B2 Gas sensing device STICHTING IMEC NEDERLAND (NL) 2013-09-03 US claimed
EP-2232240-B1 GAS SENSING DEVICE STICHTING IMEC NEDERLAND (NL) 2012-08-08 EP claimed
US-20100264333-A1 Gas Sensing Device STICHTING IMEC NEDERLAND (NL) 2010-10-21 US claimed
EP-2232240-A1 GAS SENSING DEVICE Stichting IMEC Nederland (NL) 2010-09-29 EP claimed
WO-2009077557-A1 GAS SENSING DEVICE STICHTING IMEC NEDERLAND (NL) 2009-06-25 WO claimed
EP-1300396-B1 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF EISAI R&D MAN CO LTD (JP) 2009-01-14 EP claimed
US-20050245581-A1 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-03 US claimed
US-6949571-B2 1,2-dihydropyridine compounds, process for preparation of the same and use thereof EISAI CO., LTD. (JP) 2005-09-27 US claimed
US-20040023973-A1 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof CATALYST PHARMACEUTICALS, INC. 2004-02-05 US claimed
EP-1300396-A1 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF Eisai Co., Ltd. (JP) 2003-04-09 EP claimed
US-7939549-B2 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-10 US disclosed
US-20100297181-A1 AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-11-25 US disclosed
US-20100256191-A1 AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-10-07 US disclosed
US-20100222354-A1 AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain EISAI R & D MANAGEMENT CO., LTD. (JP) 2010-09-02 US disclosed
EP-2222296-A2 AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY Eisai R&D Management Co., Ltd. (JP) 2010-09-01 EP disclosed
US-6949571-B2 1,2-dihydropyridine compounds, process for preparation of the same and use thereof EISAI CO., LTD. (JP) 2005-09-27 US disclosed
EP-1465626-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES Eisai Co., Ltd. (JP) 2004-10-13 EP disclosed
US-20040023973-A1 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof CATALYST PHARMACEUTICALS, INC. 2004-02-05 US disclosed
WO-2003047577-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES EISAI CO LTD (JP) 2003-06-12 WO disclosed
EP-1300396-A1 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF Eisai Co., Ltd. (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023973-A1 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof GRIK1, GRIK2, GRIK4 GRIA1 14/4885GRIA3 58/4885PDE4D 2584/4885
US-20050245581-A1 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof GRIK1, GRIK2, GRIK5 GRIA1 24/4885GRIA3 46/4885PDE4D 1607/4885
US-20100256191-A1 AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY GRIK5, GABRE, GABRA5 GRIA1 47/4885GRIA3 34/4885PDE4D 1445/4885
US-20100222354-A1 AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain AKR1B1, AKR1C1, AKR1C2 GRIA1 24/4885GRIA3 56/4885PDE4D 2521/4885
US-20100297181-A1 AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ GRIK5, GRIK4, GRIK1 GRIA1 34/4885GRIA3 31/4885PDE4D 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.